Tag: Novartis
Novartis: title on the rise, a broker adjusts its advice
(CercleFinance.com) – Novartis gained almost 2% in Zurich after Stifel today raised its recommendation on the stock from Hold to Buy. Similarly, the analyst is raising its price target from…
Novartis: the new antimalarial project enters phase 3
(CercleFinance.com) – Novartis announced on Wednesday that it has taken the decision, with Medicines for Malaria Venture (MMV), to advance their drug project against malaria caused by the parasite plasmodium…
Novartis: New data on cholesterol-lowering Leqvio
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Novartis: Sandoz strengthens its production of antibiotics
(CercleFinance.com) – Sandoz, the generic drugs subsidiary of Novartis, announced on Monday its intention to strengthen its antibiotic production facilities in Austria. The company plans to invest 50 million euros…
43 percent lower net profit – Novartis with significant profit decline in the 3rd quarter – News
43 percent less net profit – Novartis with significant profit decline in the 3rd quarter – News – SRF Skip to content News Business Current article contents Novartis reported a…
Novartis: positive phase III data in PNH
(CercleFinance.com) – Novartis reports that in the phase III APPLY-PNH study, its investigational oral monotherapy iptacopan demonstrated clinically significant superiority over anti-C5 treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH…
Novartis: UBS lowers its price target
(CercleFinance.com) – The analyst has low confidence in the group’s growth aspirations. He confirms his neutral advice on the value and lowers his target price to 80 CHF (from 86…
Novartis: Jefferies confirms its price target
(CercleFinance.com) – Jefferies maintains its Buy recommendation and its price target of CHF 100 on the Novartis share. ‘The changes resulting from the ongoing reorganization are obvious,’ begins the analyst,…
Novartis unveils a new strategic plan around the United States and eight drug brands
ZURICH, Sept 22 (Reuters) – Novartis on Thursday announced a new strategic plan aimed at making U.S. growth a top priority and focusing on eight drug brands the company says…
Novartis unveils a new strategic plan around the United States and eight drug brands
ZURICH (Reuters) – Novartis announced a new strategic plan on Thursday to make U.S. growth a top priority and focus on eight drug brands the company says could drive sales…
Novartis turns to the Supreme Court to protect its Gilenya in the United States
Zurich (awp) – Novartis, dismissed by the United States Court of Appeals on the validity of a patent on a dosage of its sales engine Gilenya (fingolimod), plans to bring…
Novartis to Take U.S. Drug Patent Case to Supreme Court
The decision means that HEC Pharma and other drugmakers would potentially be able to launch a generic version of Gilenya 0.5mg imminently, pending further legal action, she said. “In the…